Clinical trialEarly Phase 1Terminated
High Dose Omeprazole in Patients With Pancreatic Cancer
A Phase 0 Study of High Dose Omeprazole in Patients With Pancreatic Cancer Planning to Undergo Surgical Therapy for Evaluating Changes of Biomarkers
- Outcome
- Stopped earlyTranslational scientist left university (Other)
- Phase
- Early Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 7 September 2021
- Ended
- 3 April 2026
- Enrollment
- 25 participants
- Sites
- 1
- Primary outcomes
- Proportion; Safety and Tolerability
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 1 June 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
During this study patients will receive treatment of omeprazole at the dose depending on group enrollment * Group A will receive omeprazole 80 mg, twice a day for 12-14 days unless unacceptable toxicity * Group B, will receive omeprazole 20 mg, once a day for 12-14 days Patients will receive treatment for 2\~3 weeks during the study, and 2 months of follow up. Total accrual is anticipated to take 2 years.